We attened the 2205 ESMO Congress, that took place Oct 17-21, in Berlin, Germany. Review our poster and partner poster presentations below. Featured Presentations Scientific Posters We were proud to share ClearNote Health’s latest breakthroughs in epigenomic-based...

We will be attending the 17th Annual Next Generation Summit, taking place Aug18-20 in Washington, D.C. Don't miss our presentation in the Early Cancer Surveillance track, with the topic: Multi- and Single-Cancer Early Detection: Validation of Improved Early Screening....

Meet our team at the 15th Annual World Biomarker & CDx Summit | September 22-25, 2025 | Boston, MA. Learn more about the Virtuoso epigenomics platform, by ClearNote Health, which measures active disease biology from drug discovery through development, including...

Don't miss our poster presentation at ASCO 2025. Colorectal cancer (CRC) is the third most common cancer worldwide and a leading cause of cancer mortality, with ~33% of patients developing metastases and a poor 5-year survival rate of ~15%. While surgical resection...

Join us at DDW25 to explore how ClearNote Health is harnessing the power of the epigenome to drive early pancreatic cancer detection and transform patient outcomes. 📍 Visit us at booth #5525 to learn more about the @Avantect Pancreatic Cancer Test - a simple,...

We will be attending the AACR Annual Meeting, April 25-30, 2025, taking place at the McCormick Place Convention Center, Chicago, Illinois. Don't miss our poster presentations: Title: 5hmC-sequencing of matched cfDNA and tissue from men with mCRPC is concordant and...

ClearNote Health will be attending the 2025 ACMG Annual Clinical Genetics Meeting, March 18-22, Los Angeles. Don't miss our poster presentation: Presenter: Shimul Chowdhury, PhD, FACMG, CGMB, Vice President of Laboratory Operations Submission ID: 625881...

ClearNote Health will be at TRI-CON 2025. Meet us at booth 3 and learn more about ClearNote Health's Virtuoso Epigenomics Platform. Virtuoso leverages 5hmC epigenomic profiling to uncover active cancer biology patterns from cfDNA in plasma, empowering more efficient...

ClearNote Health's VP Translational Research & Head of Biopharma Development, Gulfem D. Guler, is attending the American Society of Clinical Oncology (ASCO) GU25 Symposium, February 13-15, San Francisco. Connect with Gulfem to learn more about ClearNote Health's...

ClearNote presented a poster entitled: “Cell-type specific signatures in plasma cell-free DNA 5-hydroxymethylome enables cancer detection and response monitoring in non-small cell lung cancer patients undergoing anti-PD-1 treatment.”